A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

This is an FIH, multicenter, open-label, dose escalation and dose expansion/dose optimization study of CT3001, which will be conducted in 2 phases: Phase 1 and Phase 2b. Phase 1 will be a standard 3+3 dose escalation and dose finding study in patients with advanced solid tumors for whom there is no available therapy (or patients are not candidates for such therapy) for the assessment of DLTs at up to 7 dose levels of CT3001. Phase 2b is a dose finding/dose optimization study of CT3001 in combination with SOC chemotherapy (FOLFOX) to evaluate the safety and preliminary efficacy of CT3001 in pat

Trial Details

NCT ID
NCT06598007
Phase
PHASE1 / PHASE2
Sponsor
Crossignal Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • CT3001
  • FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Able to give voluntary informed consent and understand the study and are willing to follow and complete all the test procedures.
  • Aged ≥ 18 years (or adult age as per local regulations).
  • Histologically/cytologically confirmed, locally advanced unresectable or metastatic solid tumors that are refractory to standard therapy, or for wh…
  • Has measurable disease per RECIST Version 1.1. that was not in a prior radiation or other locally treated area unless imaging-based progression has…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →